Viusid Administration in Subjects With Chronic Inflammatory Syndrome Under Hemodialysis Treatment
NCT ID: NCT00978224
Last Updated: 2010-07-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
SUSPENDED
PHASE3
152 participants
INTERVENTIONAL
2009-10-31
2011-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Explore the Renal Safety of Visipaque Injection 320 mgI/mL in Patients With Chronic Kidney Disease
NCT03119662
A Single Dose Study Investigating the Elimination as Well as the Tolerability of PD 0332334 in Healthy Subjects as Compared to Patients With Impaired Kidney Function.
NCT00721422
A Dose Escalation Study of VS-505 in End Stage Renal Disease Patients Undergoing Hemodialysis
NCT02469467
Study of Phosphate Levels in Patients With Chronic Kidney Disease
NCT00824460
End-stage Renal Disease (ESRD) Pilot Study
NCT03787368
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Viusid in combination with standard treatment for Chronic Inflammatory Syndrome including hemodialysis and the administration of a hypercaloric and hyperproteic diet
Viusid
3 Viusid bags (Orally administered) per day, for 60 weeks
B
Placebo in combination with standard treatment for Chronic Inflammatory Syndrome including hemodialysis and the administration of a hypercaloric and hyperproteic diet
Placebo
3 Placebo bags (Orally administered) per day, for 60 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Viusid
3 Viusid bags (Orally administered) per day, for 60 weeks
Placebo
3 Placebo bags (Orally administered) per day, for 60 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Signed informed consent
Exclusion Criteria
* Receptors of a renal graft
* Patients with malignant neoplastic conditions
* Pregnant women
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Catalysis SL
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Institute of Nephrology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mirna Atiés Sánchez, MD
Role: PRINCIPAL_INVESTIGATOR
Institute of Nephrology "Dr. Abelardo Buch López"
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institute of Nephrology "Dr. Abelardo Buch López"
Havana, , Cuba
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CAT-0907-CU
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.